Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash-to-Debt 0.13
VREX's Cash-to-Debt is ranked lower than
87% of the 261 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.52 vs. VREX: 0.13 )
Ranked among companies with meaningful Cash-to-Debt only.
VREX' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.13  Med: 0.39 Max: No Debt
Current: 0.13
0.13
No Debt
Equity-to-Asset 0.43
VREX's Equity-to-Asset is ranked lower than
80% of the 239 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.61 vs. VREX: 0.43 )
Ranked among companies with meaningful Equity-to-Asset only.
VREX' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.34  Med: 0.46 Max: 0.86
Current: 0.43
0.34
0.86
Debt-to-Equity 0.94
VREX's Debt-to-Equity is ranked lower than
84% of the 164 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.36 vs. VREX: 0.94 )
Ranked among companies with meaningful Debt-to-Equity only.
VREX' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.59  Med: 1.08 Max: 1.39
Current: 0.94
0.59
1.39
Debt-to-EBITDA 3.78
VREX's Debt-to-EBITDA is ranked lower than
76% of the 116 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.77 vs. VREX: 3.78 )
Ranked among companies with meaningful Debt-to-EBITDA only.
VREX' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 3.78  Med: 4.23 Max: 4.23
Current: 3.78
3.78
4.23
Interest Coverage 2.81
VREX's Interest Coverage is ranked lower than
83% of the 163 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 76.01 vs. VREX: 2.81 )
Ranked among companies with meaningful Interest Coverage only.
VREX' s Interest Coverage Range Over the Past 10 Years
Min: 2.81  Med: 106.25 Max: 422
Current: 2.81
2.81
422
Piotroski F-Score: 4
Altman Z-Score: 2.66
Beneish M-Score: -2.63
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating Margin % 8.25
VREX's Operating Margin % is ranked higher than
71% of the 242 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.59 vs. VREX: 8.25 )
Ranked among companies with meaningful Operating Margin % only.
VREX' s Operating Margin % Range Over the Past 10 Years
Min: 8.25  Med: 20.16 Max: 25.69
Current: 8.25
8.25
25.69
Net Margin % 5.37
VREX's Net Margin % is ranked higher than
73% of the 241 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.48 vs. VREX: 5.37 )
Ranked among companies with meaningful Net Margin % only.
VREX' s Net Margin % Range Over the Past 10 Years
Min: 5.37  Med: 12.65 Max: 16.36
Current: 5.37
5.37
16.36
ROE % 10.68
VREX's ROE % is ranked higher than
79% of the 242 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -6.75 vs. VREX: 10.68 )
Ranked among companies with meaningful ROE % only.
VREX' s ROE % Range Over the Past 10 Years
Min: 10.68  Med: 16.26 Max: 61.29
Current: 10.68
10.68
61.29
ROA % 4.15
VREX's ROA % is ranked higher than
76% of the 262 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -4.54 vs. VREX: 4.15 )
Ranked among companies with meaningful ROA % only.
VREX' s ROA % Range Over the Past 10 Years
Min: 4.15  Med: 13.55 Max: 50.84
Current: 4.15
4.15
50.84
ROC (Joel Greenblatt) % 15.90
VREX's ROC (Joel Greenblatt) % is ranked higher than
69% of the 259 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -9.57 vs. VREX: 15.90 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
VREX' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 15.9  Med: 38.32 Max: 132.5
Current: 15.9
15.9
132.5
3-Year Revenue Growth Rate 1.00
VREX's 3-Year Revenue Growth Rate is ranked lower than
99.99% of the 182 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.80 vs. VREX: 1.00 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
VREX' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -1.7  Med: -0.35 Max: 1
Current: 1
-1.7
1
3-Year EBITDA Growth Rate -14.50
VREX's 3-Year EBITDA Growth Rate is ranked lower than
99.99% of the 178 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 10.10 vs. VREX: -14.50 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
VREX' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -14.5  Med: -13.05 Max: -11.6
Current: -14.5
-14.5
-11.6
GuruFocus has detected 1 Warning Sign with Varex Imaging Corp VREX.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» VREX's 30-Y Financials

Financials (Next Earnings Date: 2018-11-09)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2017

VREX Guru Trades in Q3 2017

Jim Simons 193,400 sh (New)
Chuck Royce 190,360 sh (+39.40%)
CI Can Am Small Cap 117,542 sh (+8.02%)
First Eagle Investment 1,782,645 sh (+1.35%)
Columbia Wanger 1,288,556 sh (+1.26%)
David Einhorn 665,000 sh (unchged)
Joel Greenblatt Sold Out
John Hussman 4,000 sh (-8.26%)
Paul Tudor Jones 13,961 sh (-24.00%)
Charles Brandes 41,093 sh (-36.50%)
» More
Q4 2017

VREX Guru Trades in Q4 2017

HOTCHKIS & WILEY 34,332 sh (New)
Jim Simons 431,500 sh (+123.11%)
Chuck Royce 225,329 sh (+18.37%)
Columbia Wanger 1,367,155 sh (+6.10%)
John Hussman 4,000 sh (unchged)
Charles Brandes Sold Out
First Eagle Investment 1,767,444 sh (-0.85%)
Paul Tudor Jones 6,851 sh (-50.93%)
David Einhorn 231,900 sh (-65.13%)
» More
Q1 2018

VREX Guru Trades in Q1 2018

Joel Greenblatt 37,707 sh (New)
CI Can Am Small Cap 117,542 sh (unchged)
John Hussman 4,000 sh (unchged)
Paul Tudor Jones Sold Out
David Einhorn Sold Out
First Eagle Investment 1,759,342 sh (-0.46%)
Chuck Royce 224,299 sh (-0.46%)
HOTCHKIS & WILEY 33,977 sh (-1.03%)
Jim Simons 269,200 sh (-37.61%)
» More
Q2 2018

VREX Guru Trades in Q2 2018

HOTCHKIS & WILEY 47,787 sh (+40.65%)
Jim Simons 271,900 sh (+1.00%)
John Hussman 4,000 sh (unchged)
Joel Greenblatt 32,058 sh (-14.98%)
Chuck Royce 150,788 sh (-32.77%)
First Eagle Investment 989,740 sh (-43.74%)
» More
» Details

Insider Trades

Latest Guru Trades with VREX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
First Eagle Investment 2018-06-30 Reduce -43.74%0.07%$34.97 - $38.16 $ 29.73-20%989,740
HOTCHKIS & WILEY 2018-06-30 Add 40.65%$34.97 - $38.16 $ 29.73-20%47,787
Joel Greenblatt 2018-06-30 Reduce -14.98%$34.97 - $38.16 $ 29.73-20%32,058
First Eagle Investment 2018-03-31 Reduce -0.46%$33.46 - $43.43 $ 29.73-22%1,759,342
Joel Greenblatt 2018-03-31 New Buy0.02%$33.46 - $43.43 $ 29.73-22%37,707
HOTCHKIS & WILEY 2018-03-31 Reduce -1.03%$33.46 - $43.43 $ 29.73-22%33,977
David Einhorn 2018-03-31 Sold Out 0.17%$33.46 - $43.43 $ 29.73-22%0
First Eagle Investment 2017-12-31 Reduce -0.85%$32.95 - $41.32 $ 29.73-17%1,767,444
David Einhorn 2017-12-31 Reduce -65.13%0.23%$32.95 - $41.32 $ 29.73-17%231,900
HOTCHKIS & WILEY 2017-12-31 New Buy0.01%$32.95 - $41.32 $ 29.73-17%34,332
Charles Brandes 2017-12-31 Sold Out 0.03%$32.95 - $41.32 $ 29.73-17%0
First Eagle Investment 2017-09-30 Add 1.35%$28.25 - $34.18 $ 29.73-5%1,782,645
Charles Brandes 2017-09-30 Reduce -36.50%0.01%$28.25 - $34.18 $ 29.73-5%41,093
Joel Greenblatt 2017-09-30 Sold Out 0.05%$28.25 - $34.18 $ 29.73-5%0
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research    NAICS: 334517    SIC: 3844
Compare:SHSE:603108, NAS:AXDX, SZSE:300685, BSP:PARD3, NAS:KANG, NAS:MEDP, NAS:ALOG, SHSE:600055, NAS:GHDX, NSE:LALPATHLAB, NAS:ABAX, NAS:BEAT, TSE:4694, SZSE:300482, SZSE:300439, SZSE:300396, NAS:QDEL, TSE:4282, SHSE:603127, SZSE:300244 » details
Traded in other countries:VI4.Germany,
Headquarter Location:USA
Varex Imaging Corp is engaged in designing and manufacturing of X-ray tubes, flat panel detectors, imaging software and inspection accelerators.

Varex Imaging Corp designs and manufactures X-ray imaging components. The company operates in two segments, Medical and Industrial. The Medical segment designs, manufactures, sells, and services X-ray imaging components comprising X-ray tubes, digital flat panel image detectors, high voltage connectors, ionization chambers, and buckys. The Industrial segment designs, manufactures, sells, and services Linatron X-ray accelerators, X-ray tubes, digital flat panel detectors and high voltage connectors. The company has manufacturing, research, and development operation in the United States, Europe, Philippines and China, and sales and service operations throughout the world.

Ratios

vs
industry
vs
history
PE Ratio 26.78
VREX's PE Ratio is ranked higher than
65% of the 113 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 35.00 vs. VREX: 26.78 )
Ranked among companies with meaningful PE Ratio only.
VREX' s PE Ratio Range Over the Past 10 Years
Min: 12.62  Med: 27.77 Max: 34.41
Current: 26.78
12.62
34.41
PE Ratio without NRI 26.78
VREX's PE Ratio without NRI is ranked higher than
65% of the 113 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 35.56 vs. VREX: 26.78 )
Ranked among companies with meaningful PE Ratio without NRI only.
VREX' s PE Ratio without NRI Range Over the Past 10 Years
Min: 12.61  Med: 27.77 Max: 34.41
Current: 26.78
12.61
34.41
PB Ratio 2.66
VREX's PB Ratio is ranked higher than
56% of the 245 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.02 vs. VREX: 2.66 )
Ranked among companies with meaningful PB Ratio only.
VREX' s PB Ratio Range Over the Past 10 Years
Min: 2.54  Med: 3.41 Max: 4.12
Current: 2.66
2.54
4.12
PS Ratio 1.46
VREX's PS Ratio is ranked higher than
71% of the 230 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.81 vs. VREX: 1.46 )
Ranked among companies with meaningful PS Ratio only.
VREX' s PS Ratio Range Over the Past 10 Years
Min: 1.38  Med: 1.87 Max: 2.3
Current: 1.46
1.38
2.3
Price-to-Free-Cash-Flow 21.15
VREX's Price-to-Free-Cash-Flow is ranked higher than
72% of the 80 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 29.22 vs. VREX: 21.15 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
VREX' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 15.82  Med: 20.32 Max: 27.21
Current: 21.15
15.82
27.21
Price-to-Operating-Cash-Flow 13.94
VREX's Price-to-Operating-Cash-Flow is ranked higher than
72% of the 97 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 19.94 vs. VREX: 13.94 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
VREX' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 13.26  Med: 16.04 Max: 18.65
Current: 13.94
13.26
18.65
EV-to-EBIT 22.20
VREX's EV-to-EBIT is ranked higher than
59% of the 118 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 25.06 vs. VREX: 22.20 )
Ranked among companies with meaningful EV-to-EBIT only.
VREX' s EV-to-EBIT Range Over the Past 10 Years
Min: 12.6  Med: 20.85 Max: 27.2
Current: 22.2
12.6
27.2
EV-to-EBITDA 13.99
VREX's EV-to-EBITDA is ranked higher than
65% of the 132 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 20.75 vs. VREX: 13.99 )
Ranked among companies with meaningful EV-to-EBITDA only.
VREX' s EV-to-EBITDA Range Over the Past 10 Years
Min: 10.6  Med: 15.1 Max: 18
Current: 13.99
10.6
18
EV-to-Revenue 1.89
VREX's EV-to-Revenue is ranked higher than
71% of the 242 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.24 vs. VREX: 1.89 )
Ranked among companies with meaningful EV-to-Revenue only.
VREX' s EV-to-Revenue Range Over the Past 10 Years
Min: 1.8  Med: 2.35 Max: 2.8
Current: 1.89
1.8
2.8
Current Ratio 3.16
VREX's Current Ratio is ranked higher than
61% of the 250 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.58 vs. VREX: 3.16 )
Ranked among companies with meaningful Current Ratio only.
VREX' s Current Ratio Range Over the Past 10 Years
Min: 2.91  Med: 3.3 Max: 4.94
Current: 3.16
2.91
4.94
Quick Ratio 1.42
VREX's Quick Ratio is ranked lower than
64% of the 250 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.14 vs. VREX: 1.42 )
Ranked among companies with meaningful Quick Ratio only.
VREX' s Quick Ratio Range Over the Past 10 Years
Min: 1.42  Med: 1.72 Max: 2.25
Current: 1.42
1.42
2.25
Days Inventory 174.72
VREX's Days Inventory is ranked lower than
84% of the 204 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 79.76 vs. VREX: 174.72 )
Ranked among companies with meaningful Days Inventory only.
VREX' s Days Inventory Range Over the Past 10 Years
Min: 62.66  Med: 163.83 Max: 182.79
Current: 174.72
62.66
182.79
Days Sales Outstanding 61.29
VREX's Days Sales Outstanding is ranked higher than
51% of the 204 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 67.51 vs. VREX: 61.29 )
Ranked among companies with meaningful Days Sales Outstanding only.
VREX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 61.29  Med: 70.25 Max: 85.54
Current: 61.29
61.29
85.54
Days Payable 39.14
VREX's Days Payable is ranked lower than
65% of the 187 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 63.34 vs. VREX: 39.14 )
Ranked among companies with meaningful Days Payable only.
VREX' s Days Payable Range Over the Past 10 Years
Min: 37.52  Med: 44.34 Max: 48.35
Current: 39.14
37.52
48.35

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio 0.70
VREX's 3-Year Average Share Buyback Ratio is ranked lower than
99.99% of the 180 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -7.90 vs. VREX: 0.70 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
VREX' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: 0.7  Med: 0.8 Max: 0.9
Current: 0.7
0.7
0.9

Valuation & Return

vs
industry
vs
history
Price-to-Tangible-Book 10.73
VREX's Price-to-Tangible-Book is ranked lower than
90% of the 207 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.46 vs. VREX: 10.73 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
VREX' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 5.03  Med: 18.79 Max: 62.71
Current: 10.73
5.03
62.71
Price-to-Median-PS-Value 0.78
VREX's Price-to-Median-PS-Value is ranked lower than
51% of the 193 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.01 vs. VREX: 0.78 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
VREX' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.74  Med: 1.01 Max: 1.14
Current: 0.78
0.74
1.14
Price-to-Graham-Number 3.58
VREX's Price-to-Graham-Number is ranked lower than
72% of the 76 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.98 vs. VREX: 3.58 )
Ranked among companies with meaningful Price-to-Graham-Number only.
VREX' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 1.96  Med: 4.92 Max: 6.49
Current: 3.58
1.96
6.49
Earnings Yield (Greenblatt) % 4.47
VREX's Earnings Yield (Greenblatt) % is ranked higher than
82% of the 265 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.98 vs. VREX: 4.47 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
VREX' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 3.7  Med: 4.8 Max: 7.9
Current: 4.47
3.7
7.9

More Statistics

Revenue (TTM) (Mil) $784.30
EPS (TTM) $ 1.11
Volatility25.09%
52-Week Range $27.31 - 43.76
Shares Outstanding (Mil)38.01

Piotroski F-Score Details

Piotroski F-Score: 44
Positive ROAY
Positive CFROAY
Higher ROA yoyN
CFROA > ROAY
Lower Leverage yoyY
Higher Current Ratio yoyN
Less Shares Outstanding yoyN
Higher Gross Margin yoyN
Higher Asset Turnover yoyN

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}